1. Scrip

Novartis’s Fevipiprant Hit By Phase III Asthma Failure

ZEAL Studies Miss Efficacy In Moderate Disease

 
• By Eleanor Malone

Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.

Failed launch
Novartis's fevipiprant fails to fly in moderate asthma

Novartis AG’s asthma hopes have been dented somewhat by a Phase III miss for its small molecule candidate QAW039 (fevipiprant). In a note buried in its third-quarter results announcement, the group revealed that the oral product had failed to reach the primary efficacy endpoint of forced expiratory volume (FEV1) improvement in two Phase III trials in patients with moderate asthma. The safety profile was, however, clean.

The negative result means the weight of expectation increases for another pair of Phase III studies, LUSTER 1 and 2, which are due to read out in the first quarter of 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.